Related Experiment Video
Updated: Jan 26, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Ai Ueda1, Keiki Oikawa2, Koji Fujita2
1Department of Breast Oncology and Surgery, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Abstract:
Triple negative breast cancer (TNBC) is responsible for significant number of breast cancer-associated deaths because of lacking of successful molecular-targeted therapy. To explore a therapeutic target for TNBC, we performed a siRNA-mediated knockdown screening and identified Polo-like kinase 1 (PLK1) as a potential therapeutic target for TNBC. Knockdown of PLK1 as well as a small compound inhibitor for PLK1, BI-2536, induced G2/M arrest and created polyploid cell population, shown by increased DNA content and nuclear size. Inhibition of PLK1 eventually triggered apoptosis in multiple TNBC cell lines. In addition, we confirmed that PLK1 was significantly overexpressed in the tissues from TNBC patients compared with the tissues of normal mammary glands and benign breast tumors. Our data indicated that PLK1 plays a pivotal role in the regulation of mitosis of TNBC cells. Although future in vivo studies are warranted, targeting PLK1 by a selective inhibitor such as BI-2536 can be an attractive molecular-targeted therapy for TNBC.
Insights
Triple negative breast cancer (TNBC) lacks targeted therapies. Polo-like kinase 1 (PLK1) inhibition halts TNBC cell division and induces cell death, suggesting PLK1 as a promising therapeutic target.
Area of Science:
- Molecular Oncology
- Cancer Therapeutics
Background:
- Triple negative breast cancer (TNBC) presents a significant clinical challenge due to the absence of effective molecular-targeted therapies.
- Identifying novel therapeutic targets is crucial for improving outcomes in TNBC patients.
Purpose of the Study:
- To identify and validate potential therapeutic targets for triple negative breast cancer.
- To investigate the role of Polo-like kinase 1 (PLK1) as a therapeutic target in TNBC.
Main Methods:
- Conducted a siRNA-mediated knockdown screening to identify potential therapeutic targets.
- Utilized the PLK1 inhibitor BI-2536 to assess its effects on TNBC cell lines.
- Analyzed cell cycle progression, DNA content, nuclear size, and apoptosis induction.
Main Results:
- PLK1 was identified as a potential therapeutic target for TNBC via siRNA screening.
- Inhibition of PLK1 (using siRNA or BI-2536) induced G2/M cell cycle arrest and polyploidy.
- PLK1 inhibition triggered apoptosis in multiple TNBC cell lines and was overexpressed in TNBC tissues.
Conclusions:
- PLK1 plays a critical role in regulating mitosis in triple negative breast cancer cells.
- Targeting PLK1 with inhibitors like BI-2536 represents a potential molecular-targeted therapy for TNBC.
- Further in vivo studies are warranted to validate PLK1 as a therapeutic strategy for TNBC.
Related Concept Videos
00:46Feedback Inhibition
01:23Negative Regulator Molecules
01:06Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
01:21The Resting Membrane Potential
00:58Positive, Negative, and Zero Work
02:58Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...